Evidence map›Paper›PMID 31129747›Full record

ArticleInflammation2019

Novel Piperazino-Enaminones Decrease Pro-inflammatory Cytokines Following Hemarthrosis in a Hemophilia Mouse Model.

Chen Zhong, Doreen Szollosi, Junjiang Sun, Baolai Hua, Ola Ghoneim, Ashley Bill, Yingping Zhuang, Ivan Edafiogho

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Chen ZhongShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
Doreen SzollosiDepartment of Pharmaceutical Sciences, University of Saint Joseph, School of Pharmacy and Physician Assistant Studies, Hartford, CT, USA. dszollosi@usj.edu.
Junjiang SunDivision of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. sunjj@med.unc.edu.ORCID http://orcid.org/0000-0002-7408-0731
Baolai HuaDepartment of Hematology, Clinical Medical College, Yangzhou University, Yangzhou, China.
Ola GhoneimDepartment of Pharmaceutical Sciences, University of Saint Joseph, School of Pharmacy and Physician Assistant Studies, Hartford, CT, USA.
Ashley BillDepartment of Pharmaceutical Sciences, University of Saint Joseph, School of Pharmacy and Physician Assistant Studies, Hartford, CT, USA.
Yingping ZhuangState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Ivan EdafioghoDepartment of Pharmaceutical Sciences, University of Saint Joseph, School of Pharmacy and Physician Assistant Studies, Hartford, CT, USA.
University of Saint Joseph · USEast China University of Science and Technology · CNUniversity of North Carolina at Chapel Hill · USYangzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemarthrosis is the primary cause of hemophiliac arthropathy (HA). Pro-inflammatory cytokines are thought to play an important role in the pathogenesis of HA, and thus, anti-cytokine approaches may be used as an adjuvant therapy. A novel series of enaminone compounds (JODI), that contain the N-aryl piperazino motif, have been shown in vitro to reduce pro-inflammatory cytokines and thus may be efficacious in vivo. In this report, we will assess whether JODI can suppress multiple cytokines which might be potentially responsible for joint inflammation in a mouse model of hemarthrosis. The results showed that JODI significantly improved the survival after LPS treatment, and most pro-inflammatory cytokines/chemokines were decreased significantly after JODI administration. In the hemophilia mouse model, hemarthrosis resulted in local cytokine/chemokine changes, represented by elevated pro-inflammatory (IL-6, MCP-1, MIP-1α, MIP-1β) and pro-angiogenic (VEGF and IL-33) cytokines, and decreased anti-pro-inflammatory cytokines IL-4 and IL-10. The changes were reversed by administration of JODI, which can be used as a novel approach to manage hemophilia arthropathy.

Indexed as

AnimalsCytokinesDisease Models, AnimalHemarthrosisHemophilia AInflammationKetonesMiceNeovascularization, PathologicPiperazineCytokinesKetonesPiperazinecytokineshemarthrosishemophiliapiperazino-enaminonespro-inflammatory

Identifiers

PMID31129747
OpenAlexW2946760425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.